Leclercq Marie, Mathieu Olivier, Gomez Elena, Casellas Claude, Fenet Hélène, Hillaire-Buys Dominique
UMR 5569 Hydrosciences Montpellier, University of Montpellier I, Montpellier Cedex 5, France.
Arch Environ Contam Toxicol. 2009 Apr;56(3):408-15. doi: 10.1007/s00244-008-9202-x. Epub 2008 Sep 9.
Many pharmaceuticals are excreted in wastewater as parent substances or metabolites subsequent to therapeutic or diagnostic application in medical care. This includes the antiepileptic carbamazepine, which is not removed during conventional wastewater treatment and was found to be ubiquitous in the aquatic environment. Some carbamazepine metabolites have also been found in treated wastewater, but only five of them have been studied to date. However, at least 30 carbamazepine metabolites have been identified in humans, including some pharmacologically active or genotoxic compounds. Oxcarbazepine, an antiepileptic which is increasingly used, generates metabolites common to those of carbamazepine. The present work focuses on the presence of carbamazepine, oxcarbazepine, and seven of their metabolites (carbamazepine-10,11-epoxide, 10-hydroxy-10,11-dihydrocarbamazepine, 10,11-dihydro-10,11-trans-dihydroxycarbamazepine, 2-hydroxy-carbamazepine, iminostilbene, acridine, and acridone) at three different treatment plants (conventional activated sludge, trickling filter, and stabilization ponds) selected in France. The main aim of this work was to identify selected compounds in wastewater after therapeutic use and to measure concentrations in influents and effluents at the three wastewater treatment plants. Except for iminostilbene, all of these compounds were detected in wastewater. The metabolite common to carbamazepine and oxcarbazepine, i.e., 10,11-dihydro-10,11-trans-dihydroxycarbamazepine, was detected at a higher concentration than the parent substances in wastewater. The presence of parent molecules was noted in inlet and outlet water samples. Carbamazepine, as expected, was not removed by conventional activated sludge treatment. Nevertheless, in a wastewater treatment plant with a 78-day hydraulic retention time, a 73% decrease in carbamazepine concentration was observed. For the first time, oxcarbazepine was found in environmental samples. A decrease in oxcarbazepine concentrations was observed at the three sewage treatment plants, with removal ranging from 24 to 73%. No metabolite removal was observed after activated sludge treatment. In the two other sewage treatments plants, the fate of the metabolites differed. The concentration of some metabolites, e.g., 10,11-dihydro-10,11-trans-dihydroxycarbamazepine and acridine, increased, possibly via different processes such as cleavage of glucuronide conjugates or biotic and abiotic degradation of parent compounds. The behavior of the studied substances is discussed in terms of the treatment process and hydraulic retention time.
许多药物在医疗护理中的治疗或诊断应用后,会以母体物质或代谢物的形式排泄到废水中。这包括抗癫痫药物卡马西平,它在传统的废水处理过程中无法被去除,并且在水生环境中普遍存在。在经过处理的废水中也发现了一些卡马西平的代谢物,但迄今为止仅对其中五种进行了研究。然而,在人体中已鉴定出至少30种卡马西平代谢物,包括一些具有药理活性或基因毒性的化合物。奥卡西平是一种越来越常用的抗癫痫药物,它产生的代谢物与卡马西平的代谢物相同。本研究聚焦于法国选定的三个不同处理厂(传统活性污泥法、滴滤池法和稳定塘法)中卡马西平、奥卡西平及其七种代谢物(卡马西平 - 10,11 - 环氧化物、10 - 羟基 - 10,11 - 二氢卡马西平、10,11 - 二氢 - 10,11 - 反式 - 二羟基卡马西平、2 - 羟基 - 卡马西平、亚氨基芪、吖啶和吖啶酮)的存在情况。这项工作的主要目的是确定治疗使用后废水中选定的化合物,并测量这三个废水处理厂进水和出水中的浓度。除亚氨基芪外,所有这些化合物均在废水中被检测到。卡马西平和奥卡西平共有的代谢物,即10,11 - 二氢 - 10,11 - 反式 - 二羟基卡马西平,在废水中的检测浓度高于母体物质。在进水和出水水样中均检测到了母体分子。正如预期的那样,传统活性污泥处理无法去除卡马西平。然而,在一个水力停留时间为78天的废水处理厂中,观察到卡马西平浓度下降了73%。首次在环境样品中发现了奥卡西平。在这三个污水处理厂中均观察到奥卡西平浓度下降,去除率在24%至73%之间。活性污泥处理后未观察到代谢物的去除。在另外两个污水处理厂中,代谢物的归宿有所不同。一些代谢物的浓度,例如10,11 - 二氢 - 10,11 - 反式 - 二羟基卡马西平和吖啶,有所增加,可能是通过不同的过程,如葡糖醛酸共轭物的裂解或母体化合物的生物和非生物降解。根据处理工艺和水力停留时间对所研究物质的行为进行了讨论。